相关实验视频

Updated: Sep 20, 2025

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

激活PDE2A可以缓解异常高的cAMP/PKA对多巴胺的反应,这种反应发生在异常运动的小鼠中

Ségolène Bompierre¹, Cédric Yapo¹, Régis Blaise¹

¹Sorbonne Université, CNRS, Inserm, Institut de Biologie Paris Seine (IBPS), Center for Neuroscience at Sorbonne Université (NeuroSU), 75005, Paris, France.

Neurobiology of disease

|May 24, 2025

概括

用L-DOPA治疗帕金森病 (PD) 会导致因加大cAMP/PKA信号传递而导致动力障碍. 使用cGMP增强PDE2A活性可以减少这些过敏反应,为L-DOPA并发症提供潜在的治疗方法.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

帕金森病 (PD) 涉及多巴胺耗尽,导致运动和认知问题.
L-DOPA疗法可以缓解PD运动症状,但可能导致长期的动力障碍.
动力障碍与加剧的cAMP/PKA信号传递和改变的条纹性可塑性有关.

研究的目的:

为了研究cAMP/PKA信号在PD小鼠模型中的作用.
探索cGMP信号调节cAMP/PKA通路的潜力.
确定缓解L-DOPA诱导的运动障碍的治疗标.

主要方法:

利用基因编码的生物传感器监测cAMP和PKA信号在6-OHDA小鼠.
用DEANO (一个NO捐赠者) 刺激cGMP信号传递.
评估了DEANO对cAMP/PKA信号和PDE2A活动的影响.

主要成果:

在6-OHDA小鼠模型中,cAMP水平和PKA信号显著上调.
对cGMP信号的DEANO刺激有效地减少了过敏的cAMP/PKA反应.
这种调节是由PDE2A调节的,它有效地减少了由D1受体刺激触发的过度cAMP/PKA信号.
PDE2A表达保持不变,表明功能调制.

结论:

增强纹状体中的PDE2A活性可能会在治疗上缓解过度的cAMP/PKA信号传递.
这种方法可以减轻与L-DOPA治疗不良影响相关的长期条状神经元变化.
准PDE2A为管理帕金森病并发症提供了一个有希望的策略.

关键词:

周期性AMP是指周期性的AMP.循环的良好生产规范循环的良好生产规范多巴胺是一种多巴胺.由L-DOPA诱导的运动障碍.帕金森病的疾病.基化酶是一种基化酶.

更多相关视频

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Visualizing Protein Kinase A Activity In Head-fixed Behaving Mice Using In Vivo Two-photon Fluorescence Lifetime Imaging Microscopy

Visualizing Protein Kinase A Activity In Head-fixed Behaving Mice Using In Vivo Two-photon Fluorescence Lifetime Imaging Microscopy

Published on: June 7, 2019

相关概念视频

cAMP-dependent Protein Kinase Pathways

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...

GPCRs Regulate Adenylyl Cylase Activity

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...